HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Subscriber Sign In
 
Today@FDA
FDA Calendar
 
Archived Daily Updates
 
FDA Whistleblower
 
What do you think?
Search our 63,616-story database
Search
Renew subscription










E-mail This to a Friend | Print Format  
     
 
AstraZeneca’s Lumoxiti for Hairy Cell Leukemia
09/13/2018
 

FDA has approved AstraZeneca Pharmaceuticals’ Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for treating adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL, according to an agency release. HCL is a rare, slow-growing blood cancer in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. “As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced,” FDA says.


Approval was based on data from a single-arm, open-label clinical trial of 80 patients who had received prior treatment for HCL with at least two systemic therapies, including a purine nucleoside analog. Thirty percent of patients in the trial achieved durable complete response, and the overall response rate (number of patients with partial or complete response to therapy) was 75%, the agency says. Common side effects included infusion-related reactions, swelling caused by excess fluid in body tissue (edema), nausea, fatigue, headache, fever (pyrexia), constipation, anemia and diarrhea. A Boxed Warning is also required to advise health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels into surrounding tissues.


Post an instant comment on this report here

 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com